SCHEDULE 13G/A: BlackRock Discloses 5.4% Passive Stake in TScan Therapeutics

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 5.4% passive beneficial ownership stake in TScan Therapeutics, Inc. as of March 31, 2025.

Summary

• BlackRock, Inc. filed an Amendment No. 1 to Schedule 13G regarding its beneficial ownership in TScan Therapeutics, Inc.
• As of March 31, 2025, BlackRock beneficially owned an aggregate of 2,825,823 shares of TScan Therapeutics' Common Stock.
• This ownership represents 5.4% of the total outstanding shares of the class.
• BlackRock holds sole voting power over 2,802,967 shares and sole dispositive power over 2,825,823 shares.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
• Various BlackRock business units, including BlackRock Advisors, LLC, BlackRock Fund Advisors, and others, are involved in the beneficial ownership, with some entities individually owning 5% or greater of the outstanding shares.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The document is a routine ownership disclosure. The presence of a major institutional investor like BlackRock holding a significant stake can be viewed positively, indicating confidence without intent to interfere with management.

Positives

• The presence of a major institutional investor like BlackRock holding a significant stake (5.4%) can be interpreted as a vote of confidence in TScan Therapeutics.
• The passive nature of the investment, as indicated by the Schedule 13G filing, suggests BlackRock is not seeking to influence management or control, which can provide stability and reassurance to current management and other investors.

Future Outlook

This filing is an ownership disclosure and does not contain forward-looking statements or guidance regarding TScan Therapeutics' future performance or BlackRock's investment strategy beyond the passive nature of the holding.

Management Comments

• BlackRock, Inc. certified that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.

Industry Context

This filing is a routine disclosure by a large institutional asset manager, BlackRock, regarding its passive investment in a biotechnology company, TScan Therapeutics. Such filings are common and reflect portfolio management activities rather than specific industry trends, though the investment itself indicates BlackRock's continued interest in the therapeutics sector.

Comparison to Industry Standards

• This document is a standard Schedule 13G filing, which is a regulatory requirement for passive investors holding over 5% of a company's stock. It adheres to SEC disclosure standards.
• The filing does not contain financial results or operational metrics of TScan Therapeutics that would allow for a direct comparison against industry standards or specific comparable companies/projects.

Stakeholder Impact

• Shareholders: Provides transparency on a significant institutional holding, potentially reinforcing confidence due to BlackRock's presence.
• Management: Reassures management that a large shareholder is passive and not seeking control.

Key Dates

Keywords

TScan Therapeutics, BlackRock, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Passive Investment, SEC Filing, Biotechnology, Therapeutics